Deutsche Bank AG Purchases Shares of 24,080 LeMaitre Vascular, Inc. $LMAT

Key Points

• Deutsche Bank acquired 24,080 LeMaitre Vascular shares worth approximately $2.31 million, while institutional investors and hedge funds collectively own 84.64% of the company.
• Analyst sentiment has weakened, with several firms downgrading the stock to “Hold.” LeMaitre Vascular has an average rating of “Hold” and an average price target of $110.60.
• The company reported quarterly revenue growth of 9.6% year over year but missed earnings and revenue expectations. It also declared a quarterly dividend of $0.25 per share, representing a 1.3% annualized yield.

Deutsche Bank AG purchased a new stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 24,080 shares of the medical instruments supplier's stock, valued at approximately $2,311,000. Deutsche Bank AG owned approximately 0.11% of LeMaitre Vascular at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Sound Income Strategies LLC raised its holdings in shares of LeMaitre Vascular by 425.6% in the first quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier's stock valued at $25,000 after purchasing an additional 183 shares during the last quarter. Catalyst Capital Advisors LLC acquired a new position in LeMaitre Vascular during the first quarter worth $32,000. Geneos Wealth Management Inc. boosted its holdings in LeMaitre Vascular by 250.3% during the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier's stock worth $47,000 after purchasing an additional 398 shares during the last quarter. EverSource Wealth Advisors LLC bought a new position in LeMaitre Vascular in the second quarter valued at $47,000. Finally, Quarry LP grew its position in LeMaitre Vascular by 267.2% in the third quarter. Quarry LP now owns 727 shares of the medical instruments supplier's stock valued at $64,000 after purchasing an additional 529 shares in the last quarter. 84.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Wells Fargo & Company reduced their price objective on shares of LeMaitre Vascular from $104.00 to $94.00 and set an "equal weight" rating for the company in a research note on Wednesday, August 5th. Wall Street Zen lowered LeMaitre Vascular from a "buy" rating to a "hold" rating in a report on Saturday, August 1st. Weiss Ratings cut LeMaitre Vascular from a "buy (b-)" rating to a "hold (c+)" rating in a research report on Friday, August 14th. Barrington Research downgraded LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Wednesday, August 5th. Finally, Zacks Research lowered LeMaitre Vascular from a "strong-buy" rating to a "hold" rating in a research report on Monday, July 6th. Three equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Hold" and an average target price of $110.60.

LeMaitre Vascular Stock Performance

Shares of NASDAQ LMAT opened at $79.67 on Friday. The company has a current ratio of 16.31, a quick ratio of 13.96 and a debt-to-equity ratio of 0.40. LeMaitre Vascular, Inc. has a 12 month low of $78.27 and a 12 month high of $118.01. The stock has a 50 day moving average of $93.31 and a 200-day moving average of $99.46. The company has a market capitalization of $1.82 billion, a P/E ratio of 27.95, a P/E/G ratio of 2.30 and a beta of 0.53.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last posted its quarterly earnings results on Tuesday, August 4th. The medical instruments supplier reported $0.74 earnings per share for the quarter, missing analysts' consensus estimates of $0.81 by ($0.07). LeMaitre Vascular had a net margin of 25.02% and a return on equity of 15.63%. The business had revenue of $70.38 million during the quarter, compared to the consensus estimate of $71.47 million. During the same quarter last year, the company posted $0.60 EPS. The firm's revenue was up 9.6% on a year-over-year basis. As a group, equities research analysts predict that LeMaitre Vascular, Inc. will post 2.89 EPS for the current year.

LeMaitre Vascular Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 3rd. Investors of record on Thursday, August 20th will be issued a dividend of $0.25 per share. The ex-dividend date of this dividend is Thursday, August 20th. This represents a $1.00 annualized dividend and a dividend yield of 1.3%. LeMaitre Vascular's payout ratio is presently 35.09%.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company's offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre's product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.

Want to see what other hedge funds are holding LMAT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source